

UK NEQAS

Education | Quality | Global

2026-2027

SERVICES AVAILABLE

EQA programme directory for all
UK NEQAS schemes.

CELLULAR PATHOLOGY

CLINICAL CHEMISTRY

GENOMICS

HAEMATOLOGY

IMMUNOLOGY

MEDICAL MICROBIOLOGY

REPRODUCTIVE SCIENCE

CONTENTS

Introduction	PAGE 3
Cellular Pathology	PAGE 4-5
	Cellular Pathology Technique
	Immunocytochemistry and In-Situ Hybridisation
Clinical Chemistry	PAGE 5-6
	Birmingham Quality
	Cardiac Markers
	Edinburgh Peptide Hormones
	Guildford Peptide Hormones and Trace Elements
Genomics	PAGE 7-9
	GenQA
Haematology	PAGE 9-12
	Blood Transfusion Laboratory Practice (BTLP)
	Blood Coagulation
	Haematology
	Leucocyte Immunophenotyping
Immunology	PAGE 12-13
	Histocompatibility and Immunogenetics
	Immunology, Immunochemistry and Allergy (IIA)
Medical Microbiology	PAGE 14-15
	Microbiology
	Parasitology
Reproductive Science	PAGE 15
	Reproductive Science
Point of Care Testing	PAGE 16
PrepQ	PAGE 17
Participating Countries	PAGE 18-19
Programme Index	PAGE 20-29
UK NEQAS Centre Contacts	PAGE 30

INTRODUCTION

UK NEQAS is a world leader in External Quality Assessment (EQA), providing independent, impartial, not-for-profit services since 1969. We provide a multidisciplinary range of clinically relevant programmes that support diagnostic testing worldwide, helping laboratories deliver the highest standards of patient care.

Education and Support

Education is at the heart of UK NEQAS. We work in partnership with users to improve performance through regular quality assessment, benchmarking, and sharing best practices. Participants benefit from up-to-date guidance, troubleshooting support, and clinically relevant insights. By challenging laboratories at critical decision-making limits, UK NEQAS strengthens diagnostic reliability and contributes directly to better patient outcomes.

Innovation and Collaboration

Our expert teams comprise highly experienced healthcare scientists and clinicians, ensuring that services remain relevant and forward-looking. With in-depth knowledge of new technologies, UK NEQAS develops EQAs for innovative testing at an early stage. We collaborate with manufacturers, regulatory agencies, and international advisors to resolve issues with assays, analysers, and kits, and to support the development of new products.

Accreditation and Global Reach

All UK NEQAS centres are accredited to ISO/IEC 17043. We operate over 400 accredited programmes across more than 175 countries, making UK NEQAS a trusted partner in global healthcare. Our services are open to all diagnostic service providers - public, private, veterinary, research - as well as diagnostic manufacturers and pharmaceutical companies, ensuring benefits for patients worldwide.

Clinical Impact

The importance of EQA cannot be overstated. In the UK alone, the NHS performs over 1.25 billion laboratory tests annually, with more than 95% of clinical pathways relying on results. UK NEQAS programmes not only help laboratories monitor and benchmark their performance but also provide tools for continuous audit, quality improvement, and staff education. Participation in EQA is essential for laboratories seeking ISO 15189 accreditation and is a vital part of patient safety.

Governance and Structure

UK NEQAS operates as a consortium of 16 specialised centres hosted by NHS Trusts, universities, the UK Health Security Agency, and not-for-profit organisations. Each Member Scheme is led by an Organiser, accountable to the UK NEQAS Board of Trustees, and supported by scientific and administrative teams. Services are delivered in accordance with the Articles of Association and Code of Practice, ensuring surpluses are reinvested into improving services.

Further guidance on programme development is provided by independent steering committees and specialist advisory groups comprised of unpaid experts, ensuring EQA remains clinically relevant and educational. Work is ongoing to strengthen these systems, ensuring the UK continues to lead in using EQA findings to improve clinical laboratory practice.


Board of Trustees

The UK NEQAS Board of Trustees oversees the Charity's activities; the Board consists of elected trustees representing the membership, and one external trustee. Their responsibilities include guiding the organisation, reviewing its operations to ensure alignment with charitable aims, ensuring UK NEQAS continues to deliver a public benefit, and assuring compliance with Charity Commission requirements. Additionally, the Board drives new initiatives, fosters harmonisation of working practices, and promotes development of EQA services while ensuring adherence to the Code of Practice by the Charity's membership.

CELLULAR PATHOLOGY

Cellular Pathology Technique	
Tel:	+44 (0) 191 816 1030
Email:	cpt@ukneqas.org.uk
Website:	www.ukneqascpt.org
Legal entity:	LabXCell Ltd
Services Available	
Slide Based	
Specialist Techniques	
Neuropathology	
Renal Biopsy Pathology	
Muscle Histochemistry	
Diagnostic Cytopathology	
Bone Marrow Trephine (BMT)	
BMT Specific Cell Targets	
Mohs Procedure	
Frozen Sections	
TEM Semi Thin Resin Sections	
Slide and Tissue Based	
Tissue Diagnostics	
Mega Blocks	
Diagnostic Cytopathology Cell Block	
Digital	
Transmission Electron Microscopy (TEM)	
Direct Immunofluorescence (DIF)	
Digital Pathology	
Digital Interpretive *	
Digital Interpretive Diagnostic Cytopathology	
Digital interpretive Capsule Sponge	
Synovial Fluid and Crystal Analysis	

**Bi-annual circulations in conjunction with iLabXCell*



Immunocytochemistry and In-Situ Hybridisation	
Tel:	+44 (0) 208 187 9174
Email:	info@ukneqasiccish.org
Website:	www.ukneqasiccish.org
Legal entity:	External Quality Assessment Services for Cancer Diagnostics CIC
Services Available	
Immunocytochemistry	
Alimentary Tract Pathology - CD117 and Associated GIST markers	
Breast Pathology - HER2	
Breast Pathology - HER2-low (Pilot)	
Breast Pathology - Hormonal Receptors ER and PR	
Breast Pathology - Hormonal Receptor ER only	
Breast Pathology - PD-L1 in Triple Negative Breast Cancer (TNBC) (Pilot)	
Breast Pathology - Ki-67 (Visual Assessment and Digital Image Analysis) (Pilot)	
Cytopathology - Cytospins or Cell Blocks	
General Pathology	
Gastric Pathology - Claudin 18.2 (Pilot)	
Gastric Pathology - HER2	
Head and Neck Pathology - p16 (Pilot)	
Head and Neck Pathology- High Risk HPV by Protein or RNA (Pilot)	
Head and Neck Pathology - PD-L1 (Pilot)	
Lymphoid Pathology	
Melanoma (Pilot)	
Mismatch Repair (MMR) Proteins	
Neuropathology	
Non-Small Cell Lung Cancer (NSCLC) - ALK	
Non-Small Cell Lung Cancer (NSCLC) - PD-L1 (Pilot)	
Non-Small Cell Lung Cancer (NSCLC) - ROS1 (Pilot)	
Non-Small Cell Lung Cancer (NSCLC) - ALK and ROS1 (Pilot)	
Sarcoma (Pilot)	

CELLULAR PATHOLOGY



Immunocytochemistry and In-Situ Hybridisation

In-Situ Hybridisation

Breast HER2 Gene Pathology
(Interpretive and Technical)

Non-Small Cell Lung Cancer (NSCLC) - ALK Gene
Translocation (Pilot)

Non-Small Cell Lung Cancer (NSCLC) - ROS1 Gene
Translocation (Pilot)

CLINICAL CHEMISTRY

Birmingham Quality

Tel:	+44 (0) 121 414 7300
Email:	birminghamquality@uhb.nhs.uk
Website:	www.birminghamquality.org.uk
Legal entity:	University Hospitals Birmingham NHS Foundation Trust

Services Available

Acute and Chronic Kidney Disease - (Creatinine, Cystatin C, eGFR and AKI)

Ammonia

Angiotensin Converting Enzyme (ACE)

Antibiotic Assays

Antifungal Assays

Clinical Chemistry (Monthly)

Erythropoietin

Faecal Haemoglobin

Faecal Markers

Faecal Pancreatic Elastase

Fluids

Fructosamine

Glycated Haemoglobins

Haematinics

Holotranscobalamin

Immunosuppressants

Interpretative Comments in Clinical Chemistry

Intrinsic Factor Antibodies

Lipid Investigations

Newborn Screening

Birmingham Quality

Paediatric Bilirubin

Plasma Metanephrines

Quantitative Amino Acids

Salivary Steroids

Serum Indices (HIL)

Specific Proteins

Steroid Hormones

Sweat Testing

Thyroglobulin

Thyroid Hormones

Total Bile Acids

Toxicology (TOX) and Therapeutic Drug Monitoring (TDM)

Urinary Catecholamines and Metabolites

Urine Chemistries

Urine Dipsticks

Vitamin Assays (Carotene, Vitamin A and E)

Vitamin D

Vitamin K



CLINICAL CHEMISTRY

Cardiac Markers	
Tel:	+44 (0) 141 440 2888
Email:	info@ukneqas-cm.org.uk
Website:	www.ukneqas-cm.org.uk
Legal entity:	NHS Greater Glasgow and Clyde
Services Available	
Cardiac Markers Schemes (Laboratory)	
Cardiac Troponin I, Cardiac Troponin T, CKMB, Myoglobin, NT-proBNP	
B-Type Natriuretic Peptide (BNP)	
Cardiac Markers Schemes (Point of Care)	
Cardiac Troponin I, Cardiac Troponin T, CKMB, Myoglobin, NT-proBNP	
Edinburgh Peptide Hormones	
Tel:	+44 (0) 131 242 6885
Email:	ukneqas@ed.ac.uk
Website:	www.edqas.org
Legal entity:	NHS Lothian
Services Available	
Maternal Serum Screening	
1st Trimester (Down's Syndrome and Trisomies T13 and T18)	
1st Trimester (Down's Syndrome using Dried Blood Spots) (Pilot)	
2nd Trimester (Down's Syndrome)	
2nd Trimester (Neural Tube Defects)	
Pre-eclampsia Markers	
Placental Growth Factor (PLGF)	
sFlt-1	
sFlt-1: PLGF Ratio	
Pre-eclampsia Markers Point-of-Care (POCT)	
Placental Growth Factor (PLGF)	
Peptide I	
FSH, LH, AMH, Prolactin, Macroprolactin and Growth Hormone	
Peptide II	
PTH, ACTH and Calcitonin	

Edinburgh Peptide Hormones	
Tumour Markers	
AFP, CEA and hCG	
Pregnancy Testing	
Urinary hCG (Qualitative and Quantitative)	
Liver Fibrosis Markers	
Type III Procollagen Peptide (PIIINP)	
Hyaluronic Acid	
Tissue Inhibitor of Metalloproteinase I (TIMP-I)	
Enhanced Liver Fibrosis (ELF) Score	
FIB-4 Score	
Guildford Peptide Hormones and Trace Elements	
Tel:	+44 (0) 148 357 1122 ext. 3611
Email:	rsch.peptideeqa@nhs.net / rsc-tr.Guildford-EQA@nhs.net
Website:	www.ukneqasgphte.org.uk
Legal entity:	Frimley Health NHS Foundation Trust
Services Available	
Trace Elements in Serum	
Available Analytes: Copper, Zinc, Selenium, Aluminium, Cobalt, and Chromium	
Trace Elements in Whole Blood	
Available Analytes: Cobalt, Chromium, Manganese, Lead, Cadmium, Thallium, Mercury, Arsenic, Selenium, Zinc, and Magnesium	
Trace Elements in Urine	
Available Analytes: Cobalt, Chromium, Manganese, Lead, Cadmium, Thallium, Mercury, Arsenic, Copper, Selenium, Zinc, Iron, and Nickel	
Aluminium in Water and Dialysis Fluid	
Available Analytes: Aluminium	
Solid Matrix Scheme	
Available Analytes: Copper and Iron	
Guildford Peptide Hormones	
Insulin	
C-peptide	
Gastrin	
Insulin-like Growth Factor-1 (IGF-1)	
Insulin-like Growth Factor Binding Protein-3 (IGFBP3)	

GENOMICS

GenQA	
Tel:	+44 (0) 131 242 6898
Email:	info@genqa.org
Website:	www.genqa.org
Legal entity:	Oxford University Hospitals NHS Trust
Services Available	
Clinical Genetics and Genetic Counselling	
Clinical Genetics - Cardiovascular Disorders	
Clinical Genetics - Dysmorphology	
Clinical Genetics - Monogenic Disorders	
Clinical Genetics - Oncogenetics	
Genetic counselling - Oncogenetics	
Genetic counselling - Rare and Inherited Disorders	
Genomic and Inherited Disorders	
Ataxia and Hereditary Spastic Paraplegia (HSP)	
Cardiac Disorders	
Charcot Marie Tooth Disease and Related Sensory and Motor Neuropathies	
Chromosome Instability Syndromes ^a	
Cystic Fibrosis and <i>CFTR</i> -related Disorders	
Developmental Delay ^a	
Differences in Sex Development (DSD) ^a	
Epilepsy Disorders	
Eye Disorders	
Familial Colorectal Cancer and Polyposis	
Familial Endocrine Tumour Predisposition Disorders	
Familial Hypercholesterolaemia	
Fragile X Syndrome and <i>FMR1</i> -related Disorders	
Gastroenterology and Hepatology Disorders	
Hereditary Breast and Ovarian Cancer (HBOC) Disorders	
Huntington Disease (HD) and DRPLA	
Hypotonic Infant ^a	
Imprinting Disorders ^a	
Inborn Errors of Metabolism (IEM)	
Infertility ^a	
Inherited Cytopenias	
Interpretation of RNA Splicing Variants	

GenQA
Microdeletion Syndromes ^a
Mitochondrial Disease
Muscular Dystrophies
Neurodegenerative Disorders
Neurofibromatosis and Rasopathies
Optical Genome Mapping - Rare Disease
Parathyroid and Calcium Regulation Disorders
Postnatal Constitutional Copy Number Variants (CNV) Detection ^{a,c}
Postnatal Karyotyping ^b
Primary Immunodeficiency Disorders (PID)
Renal Disorders
Respiratory Disorders
Skeletal Dysplasia (Including Osteogenesis Imperfecta)
Trio sequencing – postnatal (neonatal and paediatric) ^a
Variant Validation ^a
X-inactivation
Haematological Neoplasms
Acute Lymphoblastic Leukaemia (ALL)
Bone Marrow Failure Syndromes (Pilot)
Chronic Lymphocytic Leukaemia (CLL)
Chronic Lymphocytic Leukaemia (CLL) <i>IGHV</i> Mutation Status
Chronic Lymphocytic Leukaemia (CLL) <i>TP53</i> Analysis
Haematological Technical FISH
Lymphoma
Myeloid disorders
Myeloma
Optical Genome Mapping - Haematological Neoplasms
Molecular Newborn Screening
Cystic Fibrosis (CF)
Medium-chain acyl-CoA Dehydrogenase Deficiency (MCADD)

a: suitable for molecular and cytogenomic testing (including Clinical Pathway EQAs)

b: suitable for cytogenomic testing only

c: EQAs offered in collaboration with EMQN

GENOMICS



GenQA
Severe Combined Immunodeficiency (SCID)
Spinal Muscular Atrophy (SMA)
Molecular Pathology
BRCA Testing for Ovarian and Prostate Cancer - Somatic ^c
BRCA Testing for Ovarian, Breast, Prostate and Pancreatic Cancer - Germline ^c
BRCA Testing for Prostate Cancer - cfDNA ^c
Breast Cancer
Breast Cancer - Tumour Expression Profiling
Central Nervous System (CNS) Tumours
Cholangiocarcinoma
Circulating Free (cf) DNA in Lung Cancer ^c
Colorectal Cancer - Core
Colorectal Cancer - MMR (MSI)
Endometrial Tumours
Gastrointestinal Stromal Tumours (GIST)
Genitourinary Tract Tumours
Homologous Recombination Repair (HRD) Testing
Lung Cancer - Comprehensive (Molecular)
Lung Cancer - EGFR
Lung cancer - Fusions (Molecular)
Melanoma
Microsatellite Instability (MSI)
Molecular Tissue Identification
NTRK Fusions
Sarcoma
Solid Tumour FISH
Thyroid Cancer
Multidisciplinary Team Working (MDT)
Genomic Molecular Tumour Board (MTB) for Solid Tumours
Genomic Multidisciplinary Team (MDT) Working for Rare Disease

GenQA
Pharmacogenomics
Pharmacogenomics: Aminoglycoside Ototoxicity
Pharmacogenomics: APOE
Pharmacogenomics: CYP2C19
Pharmacogenomics: DPYD
Pharmacogenomics: Panel
Pharmacogenomics: <i>TPMT</i> and <i>NUDT15</i>
Pharmacogenomics: <i>UGT1A1</i>
Preimplantation Genetic Testing (PGT)
PGT of Blastomere (FISH)
PGT for Aneuploidies (PGT-A)
PGT for Monogenic Disorders (PGT-M)
PGT for Structural Rearrangements (PGT-SR)
Reproductive Genomics
Maternal Cell Contamination (MCC) and Fetal Sexing
Non-Invasive Prenatal Testing (NIPT) for Aneuploidies ^c
Non-Invasive Prenatal Testing (NIPT) for Common Microdeletions
Non-Invasive Prenatal Testing (NIPT) for Fetal Sexing ^c
Pregnancy Loss
Prenatal constitutional Copy Number Variant (CNV) Detection
Prenatal Karyotyping
Rapid Prenatal Testing for Common Aneuploidies
Reproductive Carrier Screening
Trio Sequencing – Prenatal
Sample Handling
cfDNA Extraction from Plasma - Prenatal
cfDNA Extraction from Plasma - Somatic
DNA Extraction from Blood for Long Read Sequencing (LRS)
DNA Extraction from Formalin-Fixed Paraffin Embedded (FFPE) Tissue

a: suitable for molecular and cytogenomic testing (including Clinical Pathway EQAs)

b: suitable for cytogenomic testing only

c: EQAs offered in collaboration with EMQN

GENOMICS

GenQA
DNA Extraction from Fresh Tissue
DNA Extraction from Saliva
DNA Extraction from Venous Blood
DNA Quantification
Technical
Next Generation Sequencing (NGS) for Germline CNVs ^c
Next Generation Sequencing (NGS) for germline SNVs and Indels ^c
Next Generation Sequencing (NGS) for Somatic SNVs and Indels – Tumour Testing only ^c
Next Generation Sequencing (NGS) for Somatic SNVs and Indels-Tumour with Germline Subtraction Analysis ^c
Variant Classification
Classification and Interpretation of Germline SNVs and Indels
Classification of Germline SNVs and Indels
Classification of Haematological Neoplasm SNVs, CNVs and SVs
Classification of Somatic Solid Tumour SNVs, CNVs and SVs
ISCN (International System for Human Cytogenomic Nomenclature)

GenQA: Tumour Content Assessment
Viral Sequencing
SARS-CoV-2 Sequencing
GenQA: Individual Competency Assessment
GENie
Germline Variant Classification
Somatic Variant Classification
HGVS Nomenclature
ISCN
WGS/WES Proportionate Variant Analysis
Risk Calculations
Tissue-I
Breast, Central Nervous System, Gastrointestinal Tract, Gynaecological tract, Lung, Melanoma, Paediatric, Sarcoma, Thyroid and Urological Tract
<i>a: suitable for molecular and cytogenomic testing (including Clinical Pathway EQAs)</i>
<i>b: suitable for cytogenomic testing only</i>
<i>c: EQAs offered in collaboration with EMQN</i>
For more information on GenQA availability and assessment fees please visit: www.genqa.org/genie or www.genqa.org/tissuei

HAEMATOLOGY

Blood Transfusion Laboratory Practice (BTLP)	
Tel:	+44 (0) 192 358 7111
Email:	btlp@ukneqas.org.uk
Website:	www.ukneqasbtlp.org
Legal entity:	West Hertfordshire Teaching Hospitals NHS Trust
Services Available	
ABO Titration (ABOT)	
ABO Titration	
A ₁ Typing	
Direct Antiglobulin Testing (DAT)	
Detection of Cells Coated with IgG	
Detection of Cells Coated with C3d	



Blood Transfusion Laboratory Practice (BTLP)
Fetomaternal Haemorrhage (FMH)
FMH Screening
FMH Quantification
Point of Care D Typing (POCTD)
RhD Typing

HAEMATOLOGY

Blood Transfusion Laboratory Practice (BTLP)	
Pre-Transfusion Testing (PTT)	
ABO and D Grouping	
Antibody Screening	
Antibody Identification	
Crossmatching	
Rh and K Phenotyping	
Antenatal Antibody Titration (ANT) (Pilot)	
Red Cell Antibody Titration	
Extended Red Cell Phenotyping (ERP)	
Various Blood Group Antigen Phenotyping	
Red Cell Genotyping (RCG) (Pilot)	
Genotyping and Predicted Red Cell Phenotype for Various Blood Groups	
Educational	
Training, Assessment and Competency Tool (TACT)	
Screening Tests	
Prothrombin Time (PT)/INR (Venous/Capillary Methods)	
Prothrombin Time for Diagnosis (PT/Diagnostic) (PTD)	
Blood Coagulation	
Tel:	+44 (0) 114 267 3300
Email:	coag@ukneqas.org.uk
Website:	www.neqascoag.org
Legal entity:	Sheffield Teaching Hospitals NHS Foundation Trust
Services Available	
Activated Partial Thromboplastin Time (APTT)	
Heparin Dosage Assessment (HDA) by APTT	
Heparin Assay (HA) - Anti-Xa for LMWH	
Heparin Assay (HA) - Anti-Xa for UFH	
Thrombin Time (TT)	
Reptilase Time	
Fibrinogen Assay (Clauss)	
D-Dimer	
Assays	
Factor II, V, VII, VIII, IX, X, XI, XII Assays	

Blood Coagulation	
VWF Antigen Assay	
VWF Collagen-Binding Assay	
VWF Activity Assay	
Antithrombin Antigen and Activity Assay	
Protein C Antigen and Activity Assay	
Protein S Total and Free Antigen Assay	
Protein S Activity Assay	
Activated Protein C Resistance Assay	
Plasminogen Assay	
Other Programmes	
ADAMTS13 Assays	
DOAC Assays (Dabigatran, Rivaroxaban, Apixaban, Edoxaban)	
Lupus Anticoagulant Screening/Assay	
FXIII Assays	
Homocysteine Assays	
FVIII Treatment Monitoring	
FIX Treatment Monitoring	
Factor VIII Inhibitor Assay	
Emicizumab Assays	
Mixing Studies by APTT	
HIT Screening/Assays	
Molecular Genetics of Thrombophilia Testing (Factor V Leiden)	
Genetics of Heritable Bleeding and Thrombotic Disorders	




HAEMATOLOGY

Blood Coagulation	
Point of Care Testing (POCT)	
Activated Clotting Time (ACT) for: Hemochron Elite and GEM100 series ACT+, ACT-LR; i-STAT 1 and i-STAT Alinity	
INR for: CoaguChek XS, CoaguChek XS Plus, CoaguChek XS Pro and Pro II, i-STAT, LumiraDx, Xprecia Prime	
D-Dimer for: Triage, Cobas h232	
Thromboelastometry for: Rotem Sigma	
Thromboelastography for: TEG6	
Platelet Aggregometry	
Haematology	
Tel:	+44 (0) 192 358 7111
Email:	haem@ukneqas.org.uk
Website:	www.ukneqash.org
Legal entity:	West Hertfordshire Teaching Hospitals NHS Trust
Services Available	
Automated Counting and Related	
Automated Differential Leucocyte Count	
Blood Component Quality Monitoring	
Erythrocyte Sedimentation Rate	
Full Blood Count	
POCT- Haemoglobin Only	
Infectious Mononucleosis	
Plasma Viscosity	
POCT Haematology (Pilot)	
Reticulocyte Count	
Reticulocyte Haemoglobin Content (Pilot)	
Haemoglobinopathies and Thalassaemia	
Variant Haemoglobins	
DNA Diagnostics for Haemoglobinopathies	
Liquid Newborn Haemoglobinopathy Screening	
Newborn Sick Screening	
Sickle Screening Only	
Morphology Related	
Blood Films for Morphology	

Haematology
Blood Parasite Screening and Identification
Haemosiderin Staining
Manual WBC Differential Count
Rapid Diagnostic Tests for Malaria
Red Cell Enzymopathies
G6PD Screen and Quantitative Assay
Pyruvate Kinase Assay (Pilot)*
Educational
Digital Blood Film Morphology for CPD*

**not included in the current scope of accreditation*



Leucocyte Immunophenotyping	
Tel:	+44 (0) 114 267 3600
Email:	admin@ukneqasli.co.uk
Website:	www.ukneqasli.co.uk
Legal entity:	Sheffield Teaching Hospitals NHS Foundation Trust
Services Available	
Flow Cytometry	
CD34+ Stem Cell Enumeration	
Cerebrospinal Fluid (CSF) Immunophenotyping (Pilot)	
Haematological Malignancy Bone Marrow Aspirate Assessment (Pilot)	
Immune Monitoring	
Leukaemia Diagnostic Interpretation (LDI)	
Leukaemia Immunophenotyping (LI)	
Low Level Leucocyte Enumeration	
Measurable Residual Disease for ALL by Flow Cytometry	
Measurable Residual Disease for AML by Flow Cytometry (Pilot)	

HAEMATOLOGY


Leucocyte Immunophenotyping	
Flow Cytometry	
Measurable Residual Disease for CLL by Flow Cytometry (Pilot)	
Measurable Residual Disease for Plasma Cell Myeloma by Flow Cytometry (Pilot)	
Paroxysmal Nocturnal Haemoglobinuria	
CD19 CAR-T Cell Monitoring by Flow Cytometry Programme (Pilot)	
Molecular	
Myeloid Gene Panels (Pilot)	
BCR::ABL1 and AML Translocation Identification	
BCR::ABL1 Kinase Domain Variant (Mutation) Status	
BCR::ABL1 Major Quantification	
BCR::ABL1 Minor Quantification	
BRAF p.Val600Glu (V600E) Mutation Status for Hairy Cell Leukaemia	

Leucocyte Immunophenotyping	
Lymphoid Gene Panels (Pilot)	
FLT3 Mutation Status	
IG/TCR Clonality Status	
KIT p.Asp816Val (D816V) Mutation Status for Mast Cell Disease	
Lymphoplasmacytic Lymphoma / Waldenström Macroglobulinemia	
Measurable Residual Disease for AML by Molecular Methods (Pilot)	
Measurable Residual Disease for Lymphoid Neoplasms by Molecular Methods (Pilot)	
Myeloproliferative Neoplasms Diagnostic Testing (Partially Accredited)	
NPM1 Mutation Status	
Paediatric Acute Leukaemia Translocations	
Post-Stem Cell Transplant Chimerism Monitoring	

IMMUNOLOGY

Histocompatibility and Immunogenetics	
Tel:	+44 (0) 144 362 2185
Email:	UKNEQASHandI@wales.nhs.uk
Website:	www.ukneqashandi.org.uk
Legal entity:	Velindre University NHS Trust
Services Available	
Crossmatching by Flow Cytometry	
Cytotoxic Crossmatching	
DNA HLA Typing at 1st Field Resolution	
DNA HLA Typing to 2nd or 3rd Field Resolution	
Educational Cross Match	
Educational Interpretive Clinical Scenarios	
Educational HLA Typing Scheme	
HFE Typing	
HLA Antibody Detection	
HLA Antibody Specificity Analysis	
HLA Genotyping for Coeliac and other HLA Associated Diseases	
HLA Phenotyping	


Histocompatibility and Immunogenetics	
HLA-Related Pharmacogenetics	
HLA-B27 Testing	
HNA Antibody Detection/Specification	
HNA Genotyping	
HPA Antibody Detection/Specification	
HPA Genotyping	
Interpretative: HFE Genotype and Hereditary Haemochromatosis	
Interpretive HLA Genotype	
KIR Genotyping	



IMMUNOLOGY

Immunology, Immunochemistry and Allergy (IIA)	
Tel:	+44 (0) 114 271 5715
Email:	immunology@ukneqas.org.uk ukneqas@immqas.org.uk
Website:	www.immqas.org.uk
Legal entity:	Sheffield Teaching Hospitals NHS Foundation Trust
Services Available	
Allergy and Immunodeficiency	
Allergen Component Testing	
Allergen Specific IgE	
Fungal and Related Antigens	
IgG Subclasses	
Specific Microbial Antibodies (Tetanus/HiB/Pneumococcal antibodies)	
Total IgE	
Tryptase	
Autoimmunity	
Acetylcholine Receptor Antibodies	
Anaemia Related Antibodies (GPC)	
ANCA/GBM Antibodies	
Antibodies to Nuclear and Related Antigens (ANA/DNA/ENA)	
Bullous Dermatositis Antibodies	
Coeliac Disease Antibodies	
Diabetic Markers	
Ganglioside Antibodies	
Interferon Gamma Release Assays (Mycobacterium tuberculosis) IGRA TB	
Liver Disease Antibodies	
Myelin Associated Glycoprotein IgM Antibodies (MAG)	
Myositis Associated Antibodies	
NMDAR Antibodies (Pilot)	
Paraneoplastic Antibodies	
Phospholipase A2 Receptor Antibodies (PLA2R)	
Phospholipid Antibodies	
Rheumatoid Antibodies (CCP / RF)	
SARS-CoV-2 / COVID -19 Antibodies	


Immunology, Immunochemistry and Allergy (IIA)	
Scleroderma Associated Antibodies (Pilot)	
Thyroid Antibodies (TPO / TRAB)	
Digital	
Digital Cryoproteins (dCRYO)	
Digital ANA (dANA)	
Interpretative EQA (iEQA)	
Immunochemistry	
Alkaline Phosphatase (ALP) Isoenzymes	
Alpha 1 Antitrypsin and Phenotype Identification	
β2 Microglobulin	
C1 Esterase Inhibitor and Functional Complement Assays	
C-Reactive Protein (CRP)	
CSF Haem Pigments	
CSF IgG Oligoclonal Bands	
CSF Proteins and Biochemistry	
CSF β2 Transferrin/Beta Trace Protein	
Interleukin-6 (IL-6)	
Immunoglobulin D (IgD) (Pilot)	
Point of Care CRP (Pilot)	
Procalcitonin	
TNF Drugs and Antibodies (Pilot)	
Ultrasensitive C-Reactive Protein	
Oncology	
Monoclonal Protein Identification	
Prostate Specific Antigen (Total and Free PSA)	
Tumour Markers (CA125/CA199/CA153/NSE/CgA)	
Ultrasensitive PSA	



MEDICAL MICROBIOLOGY

Microbiology	
Tel:	+44 (0) 208 905 9890
Email:	organiser@ukneqas.org.uk
Website:	www.ukneqasmicro.org.uk
Legal entity:	UK Health Security Agency
Services Available	
Bacteriology	
AAFB Microscopy	
Antimicrobial Susceptibility	
Carbapenemase Producing Organisms (CPO)	
Clostridioides difficile (prev. Clostridium difficile)	
Community Medicine	
Faecal Pathogens	
General Bacteriology	
General Bacteriology and Antimicrobial Susceptibility	
Genital Pathogens	
Group B Streptococcus Screening	
Helicobacter pylori	
MRSA Screening	
Mycobacteria Culture	
Syphilis Serology	
Urinary Antigens	
Molecular	
Molecular Detection of C. trachomatis and N. gonorrhoeae	
CMV DNA Quantification	
EBV DNA Quantification	
HBV DNA Quantification	
Hepatitis C RNA Detection	
HIV 1 RNA Quantification	
Molecular Detection of Mycobacteria	
Molecular Detection of HPV	
Molecular Detection of Respiratory Viruses	
Molecular Detection of SARS-CoV-2	
Molecular Detection of Viruses in CSF	
Respiratory Viruses Point of Care	
STI Multiplex	

Microbiology
Viral Gastroenteritis (also suitable for antigen testing)
Mycology
Antifungal Susceptibility
Cryptococcal Antigen Detection
Fungal Biomarkers
Mycology
Virology
Anti-HBs Detection (suitable for point of care)
Blood Borne Viruses (suitable for point of care)
Blood Donor Screen (suitable for point of care)
CMV Detection (suitable for point of care)
EBV Detection (suitable for point of care)
Hepatitis A Detection (suitable for point of care)
Hepatitis B Serology (suitable for point of care)
Hepatitis C Serology (suitable for point of care)
Hepatitis E Detection (suitable for point of care)
HIV Serology (suitable for point of care)
Measles and Mumps IgG Serology (suitable for point of care)
Parvovirus B19 and Rubella Serology (suitable for point of care)
Point of Care
HIV Point of Care
Respiratory Viruses Point of Care
Rubella IgG Serology
VZV Serology



MEDICAL MICROBIOLOGY

Parasitology	
Tel:	+44 (0) 203 908 1371
Email:	parasite@ukneqas.org.uk
Website:	www.ukneqasmicro.org.uk/parasitology
Legal entity:	UK Health Security Agency
Services Available	
Blood Parasitology	
Faecal Parasitology	
Malaria Rapid	
Molecular Detection of Faecal Parasites	
Molecular Diagnosis of Malaria	
Parasite Serology	
Toxoplasma Serology	
Electronic Blood Parasitology	
Electronic Faecal Parasitology	
Teaching for Blood and Faecal Parasites	

REPRODUCTIVE SCIENCE

Reproductive Science	
Tel:	+44 (0) 161 276 6456/6437
Email:	repscience@ukneqas.org.uk
Website:	www.mft.nhs.uk/saint-marys/services/gynaecology/reproductive-medicine/ukneqasreproductive-science
Legal entity:	Manchester University NHS Foundation Trust
Services Available	
Andrology: Semen Analysis (Sperm Motility, Concentration and Morphology)	
Embryology: Embryo Morphology, Time Lapse Annotation	



NOTES

This image shows a single sheet of white paper with horizontal blue ruling lines. The lines are evenly spaced and run across the width of the page. There are no margins, text, or other markings on the paper.

POINT OF CARE TESTING (POCT)

Rapid growth in the use of Point of Care Testing (POCT), also known as near-patient testing (NPT), has occurred in many areas of diagnostic analysis.

With the spread of POCT, there has also been a parallel increase in the provision of External Quality Assessment (EQA) for POCT.

UK NEQAS monitors, supports and educates non-laboratory trained operators to improve the quality of diagnostic test performance and interpretation of results. We offer external quality assessment (EQA) for POCT in the following areas:

Cellular Pathology Technique
Frozen Sections
Mohs Micro Graphic Surgery

Cardiac Markers
Cardiac Troponin I (including high sensitivity assays)
Cardiac Troponin T
CKMB
Myoglobin
NT-proBNP

Clinical Chemistry (Birmingham Quality)
Clinical Chemistry
Creatinine
Glycated Haemoglobins
Lipids (Total Cholesterol, HDL Cholesterol, TC/HDL Ratio, Triglyceride, LDL Cholesterol and Non-HDL Cholesterol)
Urine Dipsticks

Edinburgh Peptide Hormones
Pre-Eclampsia Screening at Point-of-Care
Pregnancy Testing

Blood Coagulation
Activated Clotting Time (ACT) for: Hemochron Elite and GEM100 series ACT+, ACT-LR; i-STAT 1 and i-STAT Alinity
INR for: CoaguChek XS, CoaguChek XS Plus, CoaguChek XS Pro and Pro II, i-STAT, LumiraDx, Xprecia Prime
D-Dimer for: Triage, Cobas h232
Thromboelastometry for: Rotem Sigma
Thromboelastography for: TEG6
Platelet Aggregometry

Blood Transfusion Laboratory Practice (BTLP)
D-Typing

Haematology
Haemoglobin Only
POCT Haematology (PX)

Immunology, Immunochemistry & Allergy (IIA)
Point of Care CRP Testing (Pilot)

Microbiology
Cryptococcal Antigen Detection
Hepatitis B Serology
Hepatitis C Serology
Hepatitis E Detection
HIV Point of Care
Respiratory Viruses
Syphilis Serology
Urinary Antigens
Viral Gastroenteritis

Parasitology
Malaria Rapid

PRE– AND POST-ANALYTICAL QUALITY MONITORING SERVICE (PREPQ)

The control of pre- and post-analytical errors in diagnostic testing is recognised as a major contributor to the improvement in laboratory quality. Although the cause of many errors may be outside the laboratory, they waste resources and impair effective patient care.

The UK NEQAS response

UK NEQAS has developed a web-based pre- and post-analytical quality monitoring service (PrepQ), as an external comparison tool. This tool gives the laboratory the opportunity to collate and monitor the incidence of errors beyond the analytical phase against their peers.

Registering to PrepQ

Registration to the PrepQ monitoring service is flexible. It can be done by department, discipline, laboratory, hospital, or network, depending upon the individual participant's service arrangements. Regular monitoring periods allow the laboratory to return data at a frequency convenient to them against as many of the key assurance indicators as they are able to collect.

PrepQ is a web-based service

The PrepQ service is offered on a secure on-line basis through the UK NEQAS Results and Reports service. Participants submit the number of quality failures compared to the number of opportunities for failure in a given time period. Performance evaluation is reported using sigma metrics, allowing immediate benchmarking with the laboratory's peers.

Pre- and post-analytical case scenarios

PrepQ includes scenarios in pre- and post-analytical monitoring up to 4 times a year. The scenarios reflect current concerns in laboratory errors that originate outside the analytical phase. The responses are requested in the form of multiple-choice questions and brief free-text comments, and the results are reported with a short expert commentary that can be used within the laboratory for education and service development.

Is PrepQ available in your area?

Yes. PrepQ is an international programme and is available to any participant in any UK NEQAS service.

PrepQ covers a wide range of disciplines, including Blood Sciences (Haematology, Clinical Chemistry, and Immunology), Microbiology and other specialised areas.

Schedule of Exercises

PrepQ offers a regular schedule of exercises, with generous data submission windows and rapid feedback to laboratories.

The current schedule allows data submission and reports on a monthly basis. Participants are alerted by email to opening and closing dates.

Interested?

If you would like to know more about the PrepQ service, which is provided as a benefit of UK NEQAS membership, and how it could help your laboratory, please contact us on this email: prepq@ukneqas.org.uk or call us on +44 (0) 114 2611 689.

PARTICIPATING COUNTRIES

UK NEQAS is the world leading provider of clinical laboratory External Quality Assessment (EQA)/ Proficiency Testing (PT) programmes. Below, and continued on the next page, is a visual map and a list of countries currently participating in UK NEQAS EQA/PT.



A	B	C	F
Afghanistan	Bolivia	Cote d'Ivoire	Falkland Islands
Albania	Bosnia and Herzegovina	Croatia	Faroe Islands
Algeria	Botswana	Cuba	Fiji
Angola	Brazil	Curacao	Finland
Argentina	Bulgaria	Cyprus	France
Armenia	Burkina Faso	Czech Republic	French Guiana
Aruba	C	D	French Polynesia
Australia	Cambodia	Denmark	G
Austria	Cameroon	Dominican Republic	Gambia
Azerbaijan	Canada	E	Georgia
B	Central Africa Republic	Ecuador	Germany
Bangladesh	Chile	Egypt	Ghana
Barbados	China	El Salvador	Gibraltar
Belgium	Colombia	Equatorial Guinea	Greece
Benin	Congo, Democratic Republic	Estonia	Greenland
Bermuda	Costa Rica	Ethiopia	Guadeloupe

PARTICIPATING COUNTRIES

G	M	Q	U
Guatemala	Macau	Qatar	Ukraine
Guernsey	Macedonia	R	United Arab Emirates
Guinea	Madagascar	Republic of Ireland	United Kingdom
Guyana	Malawi	Republic of Korea	United States of America
H	Malaysia	Republic of Macedonia	Uruguay
Haiti	Mali	Republic of Moldova	Uzbekistan
Honduras	Malta	Reunion	V
Hong Kong	Martinique	Romania	Venezuela
Hungary	Mauritania	Rwanda	Vietnam
I	Mauritius	S	W, X, Y, Z
Iceland	Mexico	Saudi Arabia	Yemen
India	Monaco	Senegal	Zambia
Indonesia	Mongolia	Serbia	Zimbabwe
Iran	Montenegro	Sierra Leone	
Iraq	Morocco	Singapore	
Ireland	Mozambique	Sint Maarten	
Isle of Man	Myanmar	Slovak Republic	
Israel	N	Slovenia	
Italy	Namibia	South Africa	
J	Nepal	South Korea	
Jamaica	Netherlands	Spain	
Japan	New Caledonia	Sri Lanka	
Jordan	New Zealand	Sudan	
K	Nicaragua	Suriname	
Kazakhstan	Niger	Swaziland	
Kenya	Nigeria	Sweden	
Kingdom of Bahrain	Norway	Switzerland	
Kosovo	O	T	
Kuwait	Oman	Taiwan	
Kyrgyzstan	P	Tajikistan	
L	Pakistan	Tanzania	
Lao PDR	Palestine	Tchad	
Latvia	Panama	Thailand	
Lebanon	Papua New Guinea	Togo	
Lesotho	Paraguay	Tunisia	
Liberia	Peru	Turkey	
Liechtenstein	Philippines	Turkmenistan	
Lithuania	Poland	U	
Luxembourg	Portugal	Uganda	

PROGRAMME INDEX

#	Page	A	Page
1st Trimester (Down's Syndrome and Trisomies T13 and T18)	6	Andrology: Semen Analysis (Sperm Motility, Concentration and Morphology)	15
1st Trimester (Down's Syndrome using Dried Blood Spots) (Pilot)	6	Angiotensin Converting Enzyme (ACE)	5
2nd Trimester (Down's Syndrome)	6	ANT	10
2nd Trimester (Neural Tube Defects)	6	Antenatal Antibody Titration (ANT) (Pilot)	10
β2 Microglobulin	13	Antibiotic Assays	5
A		Antibodies to Nuclear and Related Antigens (ANA/DNA/ENA)	13
A1 Typing	9	Antibody Identification	10
AAFB Microscopy	14	Antibody Screening	10
ABO and D Grouping	10	Antifungal Assays	5
ABO Titration	9	Antifungal Susceptibility	14
ABOT	9	Anti-HBs Detection (suitable for point of care)	14
Acetylcholine Receptor Antibodies	13	Antimicrobial Susceptibility	14
ACTH	6	Antithrombin Antigen and Activity Assay	10
Activated Clotting Time (ACT) for: Hemochron Elite and GEM100 series ACT+, ACT-LR; i-STAT 1 and i-STAT Alinity	11, 16	Apixaban	10
Activated Partial Thromboplastin Time (APTT)	10	APTT	10
Activated Protein C Resistance Assay	10	Arsenic	6
Acute and Chronic Kidney Disease (Creatinine, Cystatin C, eGFR and AKI)	5	Assays	10
Acute Lymphoblastic Leukaemia (ALL)	7	Ataxia and Hereditary Spastic Paraplegia (HSP)	7
ADAMTS13 Assays	10	Autoimmunity	13
AFP	6	Automated Counting and Related	11
AKI	5	Automated Differential Leucocyte Count	11
Alimentary Tract Pathology - CD117 and Associated GIST Markers	4	B	
Alkaline Phosphatase (ALP) Isoenzymes	13	Bacteriology	14
Allergen Component Testing	13	BCR::ABL1 and AML Translocation Identification	12
Allergen Specific IgE	13	BCR::ABL1 Kinase Domain Variant (Mutation) Status	12
Allergy and Immunodeficiency	13	BCR::ABL1 Major Quantification	12
ALP	13	BCR::ABL1 Minor Quantification	12
Alpha-1 Antitrypsin and Phenotype Identification	13	Birmingham Quality	5-6, 16
Aluminium	6	Blood Borne Viruses (suitable for point of care)	14, 16
Aluminium in Water and Dialysis Fluid	6	Blood Coagulation	10-11, 16
AMH	6	Blood Component Quality Monitoring	11
Ammonia	5	Blood Donor Screen (suitable for point of care)	14
ANA	13	Blood Films for Morphology	11
Anaemia Related Antibodies (GPC)	13	Blood Parasite Screening and Identification	11
ANCA/GBM Antibodies	13	Blood Parasitology	15
		Blood Transfusion Laboratory Practice (BTLP)	9-10, 16

PROGRAMME INDEX

B	Page	C	Page
BMT Specific Cell Targets	4	Cardiac Troponin T	6, 16
Bone Marrow Failure Syndromes (Pilot)	7	Carotene	5
Bone Marrow Trepine (BMT)	4	CCP	13
BRAF p.Val600Glu (V600E) Mutation Status for Hairy Cell Leukaemia	12	CD19 CAR-T Cell Monitoring by Flow Cytometry Programme (Pilot)	12
BRCA Testing for Ovarian and Prostate Cancer - Somatic	8	CD34+ Stem Cell Enumeration	11
BRCA Testing for Ovarian, Breast, Prostate and Pancreatic Cancer - Germline	8	CEA	6
BRCA Testing for Prostate Cancer - cfDNA	8	CELLULAR PATHOLOGY	4-5
Breast (Tissue-I)	9	Cellular Pathology Technique	4, 16
Breast Cancer	8	Central Nervous System (CNS) Tumours	8
Breast Cancer - Tumour Expression Profiling	8	Central Nervous System (Tissue-I)	9
Breast HER2 Gene Pathology (Interpretive and Technical)	5	Cerebrospinal Fluid (CSF) Immunophenotyping (Pilot)	11
Breast Pathology - HER2	4	CF	7
Breast Pathology - HER2-low (Pilot)	4	cfDNA Extraction from Plasma - Prenatal	8
Breast Pathology - Hormonal Receptors ER and PR	4	cfDNA Extraction from Plasma - Somatic	8
Breast Pathology - Hormonal Receptors ER only	4	CgA	13
Breast Pathology - Ki-67 (Visual Assessment and Digital Image Analysis) (Pilot)	4	Charcot Marie Tooth Disease and Related Sensory and Motor Neuropathies	7
Breast Pathology - PD-L1 in Triple Negative Breast Cancer (TNBC) (Pilot)	4	Cholangiocarcinoma	8
Breast, Central Nervous System, Gastrointestinal Tract, Gynaecological Tract, Lung, Melanoma, Paediatric, Sarcoma, Thyroid and Urological Tract	9	Chromium	6
B-Type Natriuretic Peptide (BNP)	6	Chromosome Instability Syndromes	7
Bullous Dermatositis Antibodies	13	Chronic Lymphocytic Leukaemia (CLL)	7
C		Chronic Lymphocytic Leukaemia (CLL) IGHV Mutation Status	7
C1 Esterase Inhibitor and Functional Complement Assays	13	Chronic Lymphocytic Leukaemia (CLL) TP53 Analysis	7
CA125	13	Circulating Free (cf) DNA in Lung Cancer	8
CA153	13	CKMB	6, 16
CA199	13	Classification and Interpretation of Germline SNVs and Indels	9
Cadmium	6	Classification of Germline SNVs and Indels	9
Calcitonin	6	Classification of Haematological Neoplasm SNVs, CNVs and SVs	9
Carbapenemase Producing Organisms (CPO)	14	Classification of Somatic Solid Tumour SNVs, CNVs and SVs	9
Cardiac Disorders	7	CLINICAL CHEMISTRY	5-6, 16
Cardiac Markers	6, 16	Clinical Chemistry (Monthly)	5
Cardiac Markers Schemes (Laboratory)	6	Clinical Genetics - Cardiovascular Disorders	7
Cardiac Markers Schemes (Point of Care)	6	Clinical Genetics - Dysmorphology	7
Cardiac Troponin I	6, 16	Clinical Genetics - Monogenic Disorders	7
		Clinical Genetics - Oncogenetics	7

PROGRAMME INDEX

C	Page	D	Page
Clinical Genetics and Genetic Counselling	7	D-Dimer for: Triage, Cobas h232	11, 16
Clostridioides difficile (prev. Clostridium difficile)	14	Detection of Cells Coated with C3d	9
CMV Detection (suitable for point of care)	14	Detection of Cells Coated with IgG	9
CMV DNA Quantification	14	Developmental Delay	7
CNS	8	Diabetic Markers	13
CNV	7, 8	Diagnostic Cytopathology	4
Cobalt	6	Diagnostic Cytopathology Cell Block	4
Coeliac Disease Antibodies	13	Differences in Sex Development (DSD)	7
Colorectal Cancer - Core	8	Digital ANA (dANA)	13
Colorectal Cancer - MMR (MSI)	8	Digital Blood Film Morphology for CPD	11
Community Medicine	14	Digital Cryoproteins (dCRYO)	13
Copper	6	Digital Interpretive Capsule Sponge	4
Covid-19 Antibodies	13	Digital Interpretive Diagnostic Cytopathology	4
C-peptide	6	Digital Interpretive*	4
CPO	14	Digital Pathology	4
C-Reactive Protein (CRP)	13	Direct Antiglobulin Testing (DAT)	9
Creatinine	5, 16	Direct Immunofluorescence (DIF)	4
Crossmatching	10	DNA	13
Crossmatching by Flow Cytometry	12	DNA Diagnostics for Haemoglobinopathies	11
CRP	13	DNA Extraction from Blood for Long Read Sequencing (LRS)	8
CRP Point of Care (Pilot)	13	DNA Extraction from Formalin-Fixed Paraffin Embedded (FFPE) Tissue	8
Cryptococcal Antigen Detection	14, 16	DNA Extraction from Fresh Tissue	9
CSF	11,	DNA Extraction from Saliva	9
CSF Haem Pigments	13	DNA Extraction from Venous Blood	9
CSF IgG Oligoclonal Bands	13	DNA HLA Typing at 1st Field Resolution	12
CSF Proteins and Biochemistry	13	DNA HLA Typing at 2nd or 3rd Field Resolution	12
CSF β 2 Transferrin/Beta Trace Protein	13	DNA Quantification	9
Cystatin C	5	DOAC Assays (Dabigatran, Rivaroxaban, Apixaban, Edoxaban)	10
Cystic Fibrosis (CF)	7	DSD	7
Cystic Fibrosis and CFTR-related Disorders	7	D-Typing	16
Cytopathology - Cytospins or Cell Blocks	4		
Cytotoxic Crossmatching	12		
D		E	
Dabigatran	10	Edinburgh Peptide Hormones	6, 16
dANA	13	Edoxaban	10
DAT	9	Educational	10, 11
dCRYO	13	Educational Cross Match	12
D-Dimer	10, 11, 16	Educational HLA Typing Scheme	12
		Educational Interpretive Clinical Scenarios	12

PROGRAMME INDEX

E	Page	F	Page
eGFR	5	Frozen Sections	4, 16
Electronic Blood Parasitology	15	Fructosamine	5
Electronic Faecal Parasitology	15	FSH	6
Embryology: Embryo Morphology, Time-Lapse Annotation	15	Full Blood Count (FBC)	11
Emicizumab Assays	10	Fungal and Related Antigens	13
ENA	13	Fungal Biomarkers	14
Endometrial Tumours	8	FVIII Treatment Monitoring	10
Enhanced Liver Fibrosis (ELF) Score	6	FXIII Assays	10
Epilepsy Disorders	7	G	
Erythrocyte Sedimentation Rate	11	G6PD Screen and Quantitative Assay	11
Erythropoietin	5	Ganglioside Antibodies	13
Extended Red Cell Phenotyping (ERP)	10	Gastroenterology and Hepatology Disorders	7
Eye Disorders	7	Gastric Pathology - Claudin 18.2 (Pilot)	4
F		Gastric Pathology - HER2	4
Factor II, V, VII, VIII, IX, X, XI, XII Assays	10	Gastrin	6
Factor VIII Inhibitor Assays	10	Gastrointestinal Stromal Tumours (GIST)	8
Faecal Haemoglobin	5	Gastrointestinal Tract (Tissue-I)	9
Faecal Markers	5	General Bacteriology	14
Faecal Pancreatic Elastase	5	General Bacteriology and Antimicrobial Susceptibility	14
Faecal Parasitology	15	General Pathology	4
Faecal Pathogens	14	General Pathology - Claudin 18.2 (Pilot)	4
Familial Colorectal Cancer and Polyposis	7	Genetic Counselling - Oncogenetics	7
Familial Endocrine Tumour Predisposition Disorders	7	Genetic Counselling - Rare and Inherited Disorders	7
Familial Hypercholesterolaemia	7	Genetics of Heritable Bleeding and Thrombotic Disorders	10
FBC	11	GENie	9
Fetomaternal Haemorrhage (FMH)	9	Genital Pathogens	14
FFPE	8	Genitourinary Tract Tumours	8
FIB-4 Score	6	Genomic and Inherited Disorders	7
Fibrinogen Assay (Clauss)	10	Genomic Molecular Tumour Board (MTB) for Solid Tumours	8
FISH	8	Genomic Multidisciplinary Team (MDT) Working for Rare Disease	8
FIX Treatment Monitoring	10	GENOMICS	7-9
Flow Cytometry	11, 12	Genotyping and Predicted Red Cell Phenotype for Various Blood Groups	10
FLT3 Mutation Status	12	GenQA	7-9
Fluids	5	GenQA: Individual Competency Assessment	9
FMH	9	GenQA: Tumour Content Assessment	9
FMH Quantification	9	Germline Variant Classification	9
FMH Screening	9		
Fragile X Syndrome and FMR1-related Disorders	7		

PROGRAMME INDEX

G	Page	H	Page
GIST	8	HiB	13
Glycated Haemoglobins	5, 16	Histocompatibility & Immunogenetics	12
GPC	13	HIT Screening/Assays	10
Group B Streptococcus Screening	14	HIV 1 RNA Quantification	14
Growth Hormone	6	HIV Point of Care	14, 16
Guildford Peptide Hormones	6	HIV Serology (suitable for point of care)	14
Guildford Peptide Hormones and Trace Elements	6	HLA Antibody Detection	12
Gynaecological Tract (Tissue-I)	9	HLA Antibody Specificity Analysis	12
H		HLA Genotyping for Coeliac and other HLA Associated Diseases	12
HA	10	HLA Phenotyping	12
HAD	10	HLA-B27 Testing	12
Haematinics	5	HLA-Related Pharmacogenetics	12
Haematological Malignancy Bone Marrow Aspirate Assessment (Pilot)	11	HNA Antibody Detection/Specification	12
Haematological Neoplasms	7	HNA Genotyping	12
Haematological Technical FISH	7	Holotranscobalamin	5
HAEMATOLOGY	9-12, 16	Homocysteine Assays	10
Haemoglobin Only	16	Homologous Recombination Repair (HRD) Testing	8
Haemoglobinopathies and Thalassaemia	11	HPA Antibody Detection/Specification	12
Haemosiderin Staining	11	HPA Genotyping	12
HBOC	7	HRD	8
HBV DNA Quantification	14	HSP	7
hCG	6	Huntington Disease (HD) and DRPLA	7
Head and Neck Pathology - High Risk HPV by Protein or RNA (Pilot)	4	Hyaluronic Acid	6
Head and Neck Pathology - p16 (Pilot)	4	Hypotonic Infant	7
Head and Neck Pathology - PD-L1 (Pilot)	4	I	
Helicobacter pylori	14	IEM	7
Heparin Assay (HA) - Anti-Xa for LMWH	10	iEQA	13
Heparin Assay (HA) - Anti-Xa for UFH	10	IG/TCR Clonality Status	12
Heparin Dosage Assessment (HAD) by APTT	10	IgD (Pilot)	13
Hepatitis A Detection (suitable for point of care)	14	IgG Subclasses	13
Hepatitis B Serology (suitable for point of care)	14, 16	IGRA TB	13
Hepatitis C RNA Detection	14	IIA	13
Hepatitis C Serology (suitable for point of care)	14, 16	IL-6	13
Hepatitis E Detection (suitable for point of care)	14, 16	Immune Monitoring	11
Hereditary Breast and Ovarian Cancer (HBOC) Disorders	7	Immunochemistry	13
HFE Typing	12	Immunocytochemistry	4
HGVS Nomenclature	9	Immunocytochemistry and In-Situ Hybridisation	4-5
		Immunoglobulin D (IgD) (Pilot)	13
		IMMUNOLOGY	12-13

PROGRAMME INDEX

I	Page	L	Page
Immunology, Immunochemistry and Allergy (IIA)	13	Lipid Investigations	5
Immunosuppressants	5	Lipids (Total Cholesterol, HDL Cholesterol, TC/HDL Ratio, Triglyceride, LDL Cholesterol and Non-HDL Cholesterol)	16
Imprinting Disorders	7	Liquid Newborn Haemoglobinopathy Screening	11
Inborn Errors of Metabolism (IEM)	7	Liver Disease Antibodies	13
Infectious Mononucleosis	11	Liver Fibrosis Markers	6
Infertility	7	Low Level Leucocyte Enumeration	11
Inherited Cytopenias	7	LRS	8
INR for: CoaguChek XS, CoaguChek XS Plus, CoaguChek XS Pro and Pro II, i-STAT, LumiraDx, Xprecia Prime	11, 16	Lung (Tissue-I)	9
In-Situ Hybridisation	5	Lung Cancer – Comprehensive (Molecular)	8
Insulin	6	Lung Cancer - EGFR	8
Insulin-like Growth Factor (IGF-1)	6	Lung Cancer - Fusions (Molecular)	8
Insulin-like Growth Factor Binding Protein-3 (IGFBP3)	6	Lupus Anticoagulant Screening/Assay	10
Interferon Gamma Release Assays (Mycobacterium Tuberculosis) IGRA TB	13	Lymphoid Gene Panels (Pilot)	12
Interleukin-6 (IL-6)	13	Lymphoid Pathology	4
International System for Human Cytogenomic Nomenclature	9	Lymphoma	7
Interpretation of RNA Splicing Variants	7	Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia	12
Interpretative Comments in Clinical Chemistry	5	M	
Interpretative EQA (iEQA)	13	Macroprolactin	6
Interpretative HLA Genotype	12	MAG	13
Interpretative: HFE Genotype and Hereditary Haemochromatosis	12	Magnesium	6
Intrinsic Factor Antibodies	5	Malaria Rapid	15, 16
Iron	6	Manganese	6
ISCN (International System for Human Cytogenomic Nomenclature)	9	Manual WBC Differential Count	11
K		Maternal Cell Contamination (MCC) and Fetal Sexing	8
KIR Genotyping	12	Maternal Serum Screening	6
KIT p.Asp816Val (D816V) Mutation Status for Mast Cell Disease	12	MCADD	7
L		MCC	8
LDI	11	MDT	8
Lead	6	Measles and Mumps IgG Serology (suitable for point of care)	14
Leucocyte Immunophenotyping	11–12	Measurable Residual Disease for ALL by Flow Cytometry	11
Leukaemia Diagnostic Interpretation (LDI)	11	Measurable Residual Disease for AML by Flow Cytometry (Pilot)	11
Leukaemia Immunophenotyping (LI)	11	Measurable Residual Disease for AML by Molecular Methods (Pilot)	12
LH	6	Measurable Residual Disease for CLL	12
LI	11		

PROGRAMME INDEX

M	Page	M	Page
Measurable Residual Disease for Lymphoid Neoplasms by Molecular Methods (Pilot)	12	Muscular Dystrophies	7
Measurable Residual Disease for Plasma Cell Myeloma by Flow Cytometry (Pilot)	12	Mycobacteria Culture	14
MEDICAL MICROBIOLOGY	14-15	Mycology	14
Medium-chain acyl-CoA Dehydrogenase Deficiency (MCADD)	7	Myelin Associated Glycoprotein IgM Antibodies (MAG)	13
Mega Blocks	4	Myeloid Disorders	7
Melanoma	8	Myeloid Gene Panels (Pilot)	12
Melanoma (Pilot)	4	Myeloma	7
Melanoma (Tissue-I)	9	Myeloproliferative Neoplasms Diagnostic Testing (Partially Accredited)	12
Mercury	6	Myoglobin	6, 16
Microbiology	14	Myositis Associated Antibodies	13
Microdeletion Syndromes	7	N	
Microsatellite Instability (MSI)	8	Neurodegenerative Disorders	7
Mismatch Repair (MMR) Proteins	4	Neurofibromatosis and Rasopathies	7
Mitochondrial Disease	7	Neuropathology	4
Mixing Studies by APTT	10	Newborn Screening	5
Mohs Micro Graphic Surgery	16	Newborn Sickle Screening	11
Mohs Procedure	4, 16	Next Generation Sequencing (NGS) for Germline CNVs	9
Molecular	12, 14	Next Generation Sequencing (NGS) for Germline CNVs and Indels	9
Molecular Detection of C. trachomatis and N. gonorrhoeae	14	Next Generation Sequencing (NGS) for Somatic SNVs and Indels - Tumour Testing Only	9
Molecular Detection of Faecal Parasites	15	Next Generation Sequencing (NGS) for Somatic SNVs and Indels - Tumour with Germline Subtraction Analysis	9
Molecular Detection of HPV	14	NGS	9
Molecular Detection of Mycobacteria	14	Nickel	6
Molecular Detection of Respiratory Viruses	14	NMDAR Antibodies (Pilot)	13
Molecular Detection of SARS-CoV-2	14	Non-Invasive Prenatal Testing (NIPT) for Aneuploidies	8
Molecular Detection of Viruses in CSF	14	Non-Invasive Prenatal Testing (NIPT) for Common Microdeletions	8
Molecular Diagnosis of Malaria	15	Non-Invasive Prenatal Testing (NIPT) for Fetal Sexing	8
Molecular Genetics of Thrombophilia Testing (Factor V Leiden)	10	Non-Small Cell Lung Cancer (NSCLC) - ALK	4
Molecular Newborn Screening	7-8	Non-Small Cell Lung Cancer (NSCLC) - ALK and ROS1 (Pilot)	4
Molecular Pathology	8	Non-Small Cell Lung Cancer (NSCLC) - ALK Gene Translocation (Pilot)	5
Molecular Tissue Identification	8	Non-Small Cell Lung Cancer (NSCLC) - PD-L1 (Pilot)	4
Monoclonal Protein Identification	13	Non-Small Cell Lung Cancer (NSCLC) - ROS1 (Pilot)	4
Morphology Related	11		
MRSA Screening	14		
MSI	8		
Multidisciplinary Team Working (MDT)	8		
Muscle Histochemistry	4		

PROGRAMME INDEX

N	Page	P	Page
Non-Small Cell Lung Cancer (NSCLC) - ROS1 Gene Translocation (Pilot)	5	Phospholipase A2 Receptor Antibodies (PLA2R)	13
NPM1 Mutation Status	12	Phospholipid Antibodies	13
NSE	13	PID	7
NT-proBNP	6, 16	PLA2R	13
NTRK Fusions	8	Placental Growth Factor (PLGF)	6
O		Plasma Metanephries	5
Oncology	13	Plasma Viscosity	11
Optical Genome Mapping - Haematological Neoplasms	7	Plasminogen Assay	10
Optical Genome Mapping - Rare Disease	7	Platelet Aggregometry	11
P		PLGF	6
Paediatric (Tissue-I)	9	Pneumococcal	13
Paediatric Acute Leukaemia Translocations	12	POCT - Haemoglobin Only	11, 16
Paediatric Bilirubin	5	POCT - Haematology (Pilot)	11, 16
Paraneoplastic Antibodies	13	POCTD	9
Parasite Serology	15	Point of Care	14
Parasitology	15, 16	Point of Care CRP (Pilot)	13, 16
Parathyroid and Calcium Regulation Disorders	7	Point of Care D Typing (POCTD)	9
Paroxysmal Nocturnal Haemoglobinuria	12	POINT OF CARE TESTING (POCT)	16
Parvovirus B19 and Rubella Serology (suitable for point of care)	14	Postnatal Constitutional Copy Number Variants (CNV) Detection	7
Peptide I	6	Postnatal Karyotyping	7
Peptide II	6	Post-Stem Cell Transplant Chimerism Monitoring	12
PGT	8	PRE-AND POST-ANALYTICAL QUALITY MONITORING SERVICE (PREPQ)	17
PGT for Aneuploidies (PGT-A)	8	Pre-eclampsia Markers	6
PGT for Blastomere (FISH)	8	Pre-eclampsia Markers Point-of-Care (POCT)	6
PGT for Monogenic Disorders (PGT-M)	8	Pre-Eclampsia Screening at Point-of-Care	16
PGT for Structural Rearrangements (PGT-SR)	8	Pregnancy Loss	8
PGT-A	8	Pregnancy Testing	6, 16
PGT-M	8	Preimplantation Genetic testing (PGT)	8
PGT-SR	8	Prenatal Constitutional Copy Number Variant (CNV) Detection	8
Pharmacogenomics	8	Prenatal Karyotyping	8
Pharmacogenomics: Aminoglycoside Ototoxicity	8	PrepQ	17
Pharmacogenomics: APOE	8	Pre-Transfusion Testing (PTT)	10
Pharmacogenomics: CYP2C19	8	Primary Immunodeficiency Disorders (PID)	7
Pharmacogenomics: DPTD	8	Procalcitonin	13
Pharmacogenomics: Panel	8	Prolactin	6
Pharmacogenomics: TPMT and NUDT15	8	Prostate Specific Antigen (Total and Free PSA)	13
Pharmacogenomics: UGT1A1	8	Protein C Antigen and Activity Assay	10

PROGRAMME INDEX

P	Page	S	Page
Protein S Activity Assay	10	Sarcoma (Tissue-I)	9
Protein S Total and Free Antigen Assay	10	SARS-CoV-2 / Covid-19 Antibodies	13
Prothrombin Time (PT)/INR (Venous/Capillary Methods)	10	SARS-CoV-2 Sequencing	9
Prothrombin Time for Diagnosis (PT/Diagnostic) (PTD)	10	SCID	8
PTD	10	Scleroderma Associated Antibodies (Pilot)	13
PTH	6	Screening Tests	10
PTT	10	Selenium	6
Pyruvate Kinase Assay (Pilot)	11	Serum Indices (HIL)	5
Q		Severe Combined Immunodeficiency (SCID)	8
Quantitative Amino Acids	5	sFlt-1	6
R		sFlt-1: PGLF Ratio	6
Rapid Diagnostic Tests for Malaria	11	Sickle Screening Only	11
Rapid Prenatal Testing for Common Aneuploidies	8	Skeletal Dysplasia (Including Osteogenesis Imperfecta)	7
RCG (Pilot)	10	Slide and Tissue Based	4
Red Cell Antibody Titration	10	Slide Based	4
Red Cell Enzymopathies	11	SMA	8
Red Cell Genotyping (RCG) (Pilot)	10	Solid Matrix Scheme	6
Renal Biopsy Pathology	4	Solid Tumour FISH	8
Renal Disorders	7	Somatic Variant Classification	9
Reproductive Carrier Screening	8	Specialist Techniques	4
Reproductive Genomics	8	Specific Microbial Antibodies (Tetanus/HiB/Pneumococcal)	13
Reproductive Science	15	Specific Proteins	5
Reptilase Time	10	Spinal Muscular Atrophy (SMA)	8
Respiratory Disorders	7	Steroid Hormones	5
Respiratory Viruses Point of Care	14, 16	STI Multiplex	14
Reticulocyte Count	11	Sweat Testing	5
Reticulocyte Haemoglobin Content (Pilot)	11	Synovial Fluid and Crystal Analysis	4
RF	13	Syphilis Serology	14, 16
Rh and K Phenotyping	10	T	
RhD Typing	9	TACT	10
Rheumatoid Antibodies (CCP/RF)	13	Teaching for Blood and Faecal Parasites	15
Risk Calculations	9	Technical	9
Rivaroxaban	10	TEM Semi Thin Resin Sections	4
Rubella IgG Serology	14	Tetanus	13
S		Thallium	6
Salivary Steroids	5	Thrombin Time	10
Sample Handling	8-9	Thromboelastography for: TEG6	11, 16
Sarcoma	4, 8	Thromboelastometry for: Rotem Sigma	11, 16

PROGRAMME INDEX

T	Page	V	Page
Thyroglobulin	5	Variant Classification	9
Thyroid (Tissue-I)	9	Variant Haemoglobins	11
Thyroid Antibodies (TPO / TRAB)	13	Variant Validation	7
Thyroid Cancer	8	Various Blood Group Antigen Phenotyping	10
Thyroid Hormones	5	Viral Gastroenteritis (also suitable for antigen testing)	14, 16
Tissue Diagnostics	4	Viral Sequencing	9
Tissue Inhibitor of Metalloproteinase (TIMP-I)	6	Virology	14
Tissue-I	9	Vitamin A	5
TNF Drugs and Antibodies (Pilot)	13	Vitamin Assays (Carotene, Vitamin A and E)	5
Total Bile Acids	5	Vitamin D	5
Total IgE	13	Vitamin E	5
Toxicology (TOX) and Therapeutic Drug Monitoring (TDM)	5	Vitamin K	5
Toxoplasma Serology	15	VWF Activity Assay	10
TPO	13	VWF Antigen Assay	10
TRAB	13	VWF Collagen-Binding Assay	10
Trace Elements in Serum	6	VZV Serology	14
Trace Elements in Urine	6	W	
Trace Elements in Whole Blood	6	WGS/WES Proportionate Variant Analysis	9
Training, Assessment and Competency Tool (TACT)	10	X	
Transmission Electron Microscopy (TEM)	4	X-inactivation	7
Trio Sequencing - Postnatal (Neonatal and Paediatric)	7	Z	
Trio Sequencing - Prenatal	8	Zinc	6
Tryptase	13		
TT	10		
Tumour Content Assessment	9		
Tumour Markers (Clinical Chemistry)	6		
Tumour Markers (Immunology)	13		
Type III Procollagen Peptide (PIIINP)	6		
U			
Ultrasensitive C-Reactive Protein	13		
Ultrasensitive PSA	13		
Urinary Antigens	14, 16		
Urinary Catecholamines and Metabolites	5		
Urinary hCG (Qualitative and Quantitative)	6		
Urine Chemistries	5		
Urine Dipsticks	5, 16		
Urological Tract (Tissue-I)	9		

UK NEQAS CENTRE CONTACTS

UK NEQAS Centre	Telephone Number	Email Address
Birmingham Quality	+44 (0) 121 414 7300	birminghamquality@uhb.nhs.uk
Blood Coagulation	+44 (0) 114 267 3300	coag@ukneqas.org.uk
Blood Transfusion Laboratory Practice (BTLP)	+44 (0) 192 358 7111	btlp@ukneqas.org.uk
Cardiac Markers	+44 (0) 141 440 2888	info@ukneqas-cm.org.uk
Cellular Pathology Technique	+44 (0) 191 816 1030	cpt@ukneqas.org.uk
Edinburgh Peptide Hormones	+44 (0) 131 242 6885	ukneqas@ed.ac.uk
GenQA	+44 (0) 131 242 6898	info@genqa.org
Guildford Peptide Hormones & Trace Elements	+44 (0) 148 357 1122 ext. 3611	rsch.peptideeqa@nhs.net rsc-tr.Guildford-EQA@nhs.net
Haematology	+44 (0)192 358 7111	haem@ukneqas.org.uk
Histocompatibility & Immunogenetics	+44 (0) 144 362 2185	handi@ukneqas.org.uk
Immunocytochemistry & In-Situ Hybridisation (ICC&ISH)	+44 (0) 208 187 9174	info@ukneqasiccish.org
Immunology, Immunochemistry & Allergy (IIA)	+44 (0) 114 271 5715	immunology@ukneqas.org.uk
Leucocyte Immunophenotyping (LI)	+44 (0) 114 267 3600	admin@ukneqasli.co.uk
Microbiology	+44 (0) 208 905 9890	organiser@ukneqasmicro.org.uk
Parasitology	+44 (0) 203 908 1371	parasite@ukneqas.org.uk
Reproductive Science	+44 (0) 161 276 6437	repscience@ukneqas.org.uk

GENERAL ENQUIRIES

By post: UK NEQAS Central Office
Offices 5 & 6
Community Stadium
Sheffield Olympic Legacy Park
Worksop Road
Sheffield
South Yorkshire
S9 3TL
United Kingdom

Telephone: +44 (0) 114 261 1689
Email: centraloffice@ukneqas.org
Website: www.ukneqas.org.uk

QR code:



LinkedIn:  @ukneqas

YouTube:  @ukneqas6284